Phase II study of taxol combined with ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer

Alberto Zaniboni, Andrea Ardizzoni, Filippo De Marinis, Luigi Portalone, Corrado Boni, Fausto Meriggi, Mara Argenide Cafferata, Ottavio Ariganello, Valter Torri, Carlo Emilio Neumaier, Riccardo Rosso

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The objective of the present study was to evaluate the activity and the toxicity of an original combination of paclitaxel (Taxol), ifosfamide, and carboplatin in patients with stage IIIB-IV non-small-cell lung cancer (NSCLC). Sixty-one patients with previously untreated stage IIIB-IV NSCLC were enrolled by five institutions. Paclitaxel was given at the dose of 200 mg/m2 iv in 3 hours, ifosfamide (with mesna) at the dose of 3 g/m2 and carboplatin at an area under the curve 5, on day 1, every 21 days for a total of six cycles in responding or stabilized patients. Among the 59 patients evaluable for response, 2 complete remissions and 25 partial remissions were achieved for an overall response rate of 45.7% (95% CI = 32.7-59.2). According to an intention-to-treat analysis, the response rate was 44.2%. Thirteen patients had a stable disease, whereas 19 progressed. The median time to progression was 7.7 months (range: 1-18), whereas the median overall survival was 10 months (range: 1-30+). The 1-year survival rate was 43%. Hematologic toxicity was exceptionally mild, and peripheral neurologic toxicity of grade III was experienced by only three patients. There was one toxic death. This original triplet regimen based on paclitaxel, ifosfamide, and carboplatin has proved active, safe, and easy to deliver on an outpatient basis for patients with advanced NSCLC. Randomized studies both versus carboplatin-paclitaxel and other triplets are clearly warranted.

Original languageEnglish
Pages (from-to)84-88
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume26
Issue number1
DOIs
Publication statusPublished - Feb 2003

Fingerprint

Ifosfamide
Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Therapeutics
Mesna
Intention to Treat Analysis
Poisons
Peripheral Nervous System
Area Under Curve
Outpatients
Survival Rate
Survival

Keywords

  • Carboplatin
  • Chemotherapy
  • Ifosfamide
  • Non-small cell lung cancer
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II study of taxol combined with ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer. / Zaniboni, Alberto; Ardizzoni, Andrea; De Marinis, Filippo; Portalone, Luigi; Boni, Corrado; Meriggi, Fausto; Cafferata, Mara Argenide; Ariganello, Ottavio; Torri, Valter; Neumaier, Carlo Emilio; Rosso, Riccardo.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 26, No. 1, 02.2003, p. 84-88.

Research output: Contribution to journalArticle

Zaniboni, Alberto ; Ardizzoni, Andrea ; De Marinis, Filippo ; Portalone, Luigi ; Boni, Corrado ; Meriggi, Fausto ; Cafferata, Mara Argenide ; Ariganello, Ottavio ; Torri, Valter ; Neumaier, Carlo Emilio ; Rosso, Riccardo. / Phase II study of taxol combined with ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2003 ; Vol. 26, No. 1. pp. 84-88.
@article{4820035555e047e98f005cb565049172,
title = "Phase II study of taxol combined with ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer",
abstract = "The objective of the present study was to evaluate the activity and the toxicity of an original combination of paclitaxel (Taxol), ifosfamide, and carboplatin in patients with stage IIIB-IV non-small-cell lung cancer (NSCLC). Sixty-one patients with previously untreated stage IIIB-IV NSCLC were enrolled by five institutions. Paclitaxel was given at the dose of 200 mg/m2 iv in 3 hours, ifosfamide (with mesna) at the dose of 3 g/m2 and carboplatin at an area under the curve 5, on day 1, every 21 days for a total of six cycles in responding or stabilized patients. Among the 59 patients evaluable for response, 2 complete remissions and 25 partial remissions were achieved for an overall response rate of 45.7{\%} (95{\%} CI = 32.7-59.2). According to an intention-to-treat analysis, the response rate was 44.2{\%}. Thirteen patients had a stable disease, whereas 19 progressed. The median time to progression was 7.7 months (range: 1-18), whereas the median overall survival was 10 months (range: 1-30+). The 1-year survival rate was 43{\%}. Hematologic toxicity was exceptionally mild, and peripheral neurologic toxicity of grade III was experienced by only three patients. There was one toxic death. This original triplet regimen based on paclitaxel, ifosfamide, and carboplatin has proved active, safe, and easy to deliver on an outpatient basis for patients with advanced NSCLC. Randomized studies both versus carboplatin-paclitaxel and other triplets are clearly warranted.",
keywords = "Carboplatin, Chemotherapy, Ifosfamide, Non-small cell lung cancer, Paclitaxel",
author = "Alberto Zaniboni and Andrea Ardizzoni and {De Marinis}, Filippo and Luigi Portalone and Corrado Boni and Fausto Meriggi and Cafferata, {Mara Argenide} and Ottavio Ariganello and Valter Torri and Neumaier, {Carlo Emilio} and Riccardo Rosso",
year = "2003",
month = "2",
doi = "10.1097/00000421-200302000-00016",
language = "English",
volume = "26",
pages = "84--88",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Phase II study of taxol combined with ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer

AU - Zaniboni, Alberto

AU - Ardizzoni, Andrea

AU - De Marinis, Filippo

AU - Portalone, Luigi

AU - Boni, Corrado

AU - Meriggi, Fausto

AU - Cafferata, Mara Argenide

AU - Ariganello, Ottavio

AU - Torri, Valter

AU - Neumaier, Carlo Emilio

AU - Rosso, Riccardo

PY - 2003/2

Y1 - 2003/2

N2 - The objective of the present study was to evaluate the activity and the toxicity of an original combination of paclitaxel (Taxol), ifosfamide, and carboplatin in patients with stage IIIB-IV non-small-cell lung cancer (NSCLC). Sixty-one patients with previously untreated stage IIIB-IV NSCLC were enrolled by five institutions. Paclitaxel was given at the dose of 200 mg/m2 iv in 3 hours, ifosfamide (with mesna) at the dose of 3 g/m2 and carboplatin at an area under the curve 5, on day 1, every 21 days for a total of six cycles in responding or stabilized patients. Among the 59 patients evaluable for response, 2 complete remissions and 25 partial remissions were achieved for an overall response rate of 45.7% (95% CI = 32.7-59.2). According to an intention-to-treat analysis, the response rate was 44.2%. Thirteen patients had a stable disease, whereas 19 progressed. The median time to progression was 7.7 months (range: 1-18), whereas the median overall survival was 10 months (range: 1-30+). The 1-year survival rate was 43%. Hematologic toxicity was exceptionally mild, and peripheral neurologic toxicity of grade III was experienced by only three patients. There was one toxic death. This original triplet regimen based on paclitaxel, ifosfamide, and carboplatin has proved active, safe, and easy to deliver on an outpatient basis for patients with advanced NSCLC. Randomized studies both versus carboplatin-paclitaxel and other triplets are clearly warranted.

AB - The objective of the present study was to evaluate the activity and the toxicity of an original combination of paclitaxel (Taxol), ifosfamide, and carboplatin in patients with stage IIIB-IV non-small-cell lung cancer (NSCLC). Sixty-one patients with previously untreated stage IIIB-IV NSCLC were enrolled by five institutions. Paclitaxel was given at the dose of 200 mg/m2 iv in 3 hours, ifosfamide (with mesna) at the dose of 3 g/m2 and carboplatin at an area under the curve 5, on day 1, every 21 days for a total of six cycles in responding or stabilized patients. Among the 59 patients evaluable for response, 2 complete remissions and 25 partial remissions were achieved for an overall response rate of 45.7% (95% CI = 32.7-59.2). According to an intention-to-treat analysis, the response rate was 44.2%. Thirteen patients had a stable disease, whereas 19 progressed. The median time to progression was 7.7 months (range: 1-18), whereas the median overall survival was 10 months (range: 1-30+). The 1-year survival rate was 43%. Hematologic toxicity was exceptionally mild, and peripheral neurologic toxicity of grade III was experienced by only three patients. There was one toxic death. This original triplet regimen based on paclitaxel, ifosfamide, and carboplatin has proved active, safe, and easy to deliver on an outpatient basis for patients with advanced NSCLC. Randomized studies both versus carboplatin-paclitaxel and other triplets are clearly warranted.

KW - Carboplatin

KW - Chemotherapy

KW - Ifosfamide

KW - Non-small cell lung cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0037322315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037322315&partnerID=8YFLogxK

U2 - 10.1097/00000421-200302000-00016

DO - 10.1097/00000421-200302000-00016

M3 - Article

C2 - 12576930

AN - SCOPUS:0037322315

VL - 26

SP - 84

EP - 88

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -